ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.411,55
-0,27%
S&P 500
5.321,41
0,25%
US Dollar vs BRL
5,1233
0,00%
Bitcoin
70.015,00
-0,17%
Brent Oil
82,185
-0,32%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Quince Therapeutics Inc (QNCX)

  7. Quince Therapeutics Inc (QNCX) Notícias

QNCX

Quince Therapeutics (QNCX)

Quince Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:QNCX
DataHoraFonteTítuloCódigoCompanhia
13/05/202408:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QNCXQuince Therapeutics Inc
13/05/202408:00Business WireQuince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
06/05/202417:05Business WireQuince Therapeutics to Present at The Citizens JMP Life Sciences ConferenceNASDAQ:QNCXQuince Therapeutics Inc
01/04/202408:00Business WireQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
22/02/202409:00Business WireQuince Therapeutics Launches Scientific Advisory BoardNASDAQ:QNCXQuince Therapeutics Inc
15/02/202418:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
15/02/202409:00Business WireQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsNASDAQ:QNCXQuince Therapeutics Inc
07/02/202418:05Business WireQuince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:QNCXQuince Therapeutics Inc
02/02/202419:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
05/01/202418:01Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:QNCXQuince Therapeutics Inc
04/01/202418:05Business WireQuince Therapeutics to Participate at Investor Events in January 2024NASDAQ:QNCXQuince Therapeutics Inc
24/10/202320:34Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
23/10/202308:00Business WireQuince Therapeutics Completes Acquisition of EryDel S.p.A.NASDAQ:QNCXQuince Therapeutics Inc
28/09/202317:53Dow Jones NewsQuince Therapeutics to Advance Study of EryDex as FDA Lifts Application HoldNASDAQ:QNCXQuince Therapeutics Inc
28/09/202317:05Business WireU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaNASDAQ:QNCXQuince Therapeutics Inc
06/09/202308:00Business WireQuince Therapeutics Appoints Dr. Charles S. Ryan as PresidentNASDAQ:QNCXQuince Therapeutics Inc
10/08/202317:05Business WireQuince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023NASDAQ:QNCXQuince Therapeutics Inc
24/07/202318:56Business WireQuince Therapeutics rileva EryDel SpA e il suo asset di fase 3 mirato all'atassia-telangectasia, per cui attualmente non esistono trattamenti approvati, con opportunità stimate per un picco di vendite di oltre 1 miliardo di dollari USANASDAQ:QNCXQuince Therapeutics Inc
24/07/202308:00Business WireQuince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales OpportunityNASDAQ:QNCXQuince Therapeutics Inc
26/05/202318:51Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:QNCXQuince Therapeutics Inc
25/05/202317:26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:QNCXQuince Therapeutics Inc
14/04/202317:13Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:QNCXQuince Therapeutics Inc
14/04/202317:07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:QNCXQuince Therapeutics Inc
11/04/202308:00Business WireQuince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake CapitalNASDAQ:QNCXQuince Therapeutics Inc
06/04/202317:05Business WireQuince Therapeutics Engages MTS Health Partners as Independent Financial AdvisorNASDAQ:QNCXQuince Therapeutics Inc
05/04/202318:16Edgar (US Regulatory)Securities Registration (section 12(b)) (8-a12b)NASDAQ:QNCXQuince Therapeutics Inc
05/04/202317:05Business WireQuince Therapeutics Adopts Limited Duration Stockholders Rights PlanNASDAQ:QNCXQuince Therapeutics Inc
31/03/202317:01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:QNCXQuince Therapeutics Inc
22/03/202306:00Business WireQuince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake CapitalNASDAQ:QNCXQuince Therapeutics Inc
21/03/202318:10AllPennyStocks.comAnother Biotech Massively Outperforms Broader EquitiesNASDAQ:QNCXQuince Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:QNCX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BEEF3
MINERVA ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados